𝔖 Bobbio Scriptorium

✦ LIBER ✦

PCV24 CARDIOVASCULAR EVENTS REDUCTION AND COSTEFFECTIVENESS OF ATORVASTATIN VERSUS PRAVASTATIN IN SPANISH POPULATION WITH ACUTE CORONARY SYNDROME (ACS)

✍ Scribed by J F Bobadilla; JC Checa; J Soto; M García; E Martínez; G Hernández

Book ID: 119594536
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 72 KB
Volume: 9
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63640-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduction in Recurrent Cardiovascular Ev

Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes: From the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Trial

✍ Sabina A. Murphy; Christopher P. Cannon; Stephen D. Wiviott; Carolyn H. McCabe; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 227 KB

Assessment of adiponectin and the risk o

Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22)

✍ Sean R. Wilson; Marc S. Sabatine; Stephen D. Wiviott; Kausik K. Ray; James A. De 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Effect of atorvastatin on risk of recurr

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study

✍ S. Kinlay; G.G. Schwartz; A.G. Olsson 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB

Evaluating the Performance of the Can Ra

Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) and the Reduction of Atherothrombosis for Continued Health (REACH) Bleeding Scores in the Australian and New Zealand (ANZ) Acute Coronary Syndrome (ACS) Population

✍ L. Edwards; I. Ranasinghe; D. Brieger 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 88 KB